Catalyst PHARMACEUTICALS, Inc. (CPRX) intrinsic value & 10-year financials
Catalyst PHARMACEUTICALS, Inc. (CPRX) has a Graham intrinsic value of $55.80 per share. Over the last 10 fiscal years revenue grew 174.6% a year to $589.0M, with an average return on invested capital of -171.8%.
- Graham intrinsic value
- $55.80
- Revenue (FY2025)
- $589.0M
- Revenue growth (10-yr CAGR)
- 174.6%
- ROIC (10-yr avg)
- -171.8%
- Free cash flow (FY2025)
- $208.6M
CPRX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $589.0M | $214.3M | $1.68 | $208.6M | 43.8% | 84.7% |
| FY2024 | $491.7M | $163.9M | $1.31 | $239.3M | 39.7% | 63.4% |
| FY2023 | $398.2M | $71.4M | $0.63 | $143.4M | 21.8% | 50.6% |
| FY2022 | $214.2M | $83.1M | $0.75 | $116.0M | 47.5% | 360.2% |
| FY2021 | $140.8M | $39.5M | $0.37 | $59.4M | 37.2% | 99.9% |
| FY2020 | $118.7M | $75.0M | $0.71 | $45.0M | 34.8% | 216.7% |
| FY2019 | $102.3M | $31.9M | $0.30 | $34.6M | 31.1% | -2460.0% |
| FY2018 | $500.0K | -$34.0M | -$0.33 | -$25.8M | -7059.0% | -53.6% |
| FY2017 | $0 | -$18.4M | — | — | — | -31.1% |
| FY2016 | $0 | -$18.1M | — | -$18.1M | — | -49.0% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
CATALYST PHARMACEUTICALS, INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
CATALYST PHARMACEUTICALS, INC. returns on capital have been average, hovering around 14.6% ROIC over the decade.
CATALYST PHARMACEUTICALS, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, CATALYST PHARMACEUTICALS, INC. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $55.80 per share.